Skip to main content
SpringerLink
Log in

Angiostatin and Endostatin: Endogenous Inhibitors of Tumor Growth

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Considerable progress has been made in the understanding of the molecular structure and mechanistic aspects of Angiostatin and Endostatin, endogenous angiogenesis inhibitors that have been shown to regress tumors in murine models. The growing body of literature surrounding these molecules and on the efficacy of these proteins is in part due to the ability to generate these proteins in recombinant systems as well characterized molecules. Recombinant human Angiostatin and Endostatin are in Phase I trials, following the manufacture of clinical grade material at large scale. This review highlights the recent advances made on understanding the structure and function of Angiostatin and Endostatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. O'Reilly M, Rosenthal R, Sage EH, Smith S, Holmgren L, Moses M, Shing Y, Folkman J: The suppression of tumor metastases by a primary tumor. Surgical Forum 44: 474-476, 1993

    Google Scholar 

  2. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma (see comments). Cell 79: 315-28, 1994

    Google Scholar 

  3. Sim BKL, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA: A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 57: 1329-34, 1997

    Google Scholar 

  4. Wu Z, O'Reilly MS, Folkman J, Shing Y: Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun 236: 651-4, 1997

    Google Scholar 

  5. Sim BKL: Angiostatin protein and other plasminogen fragments. In: Teicher BA. (ed) Antiangiogenic Agents in Cancer Therapy, Vol. 14, Totowa, NJ: Humana Press Inc., 1998, pp 225-36

    Google Scholar 

  6. Sim BKL: Angiostatintmtm and endostatintm: endothelial cell-specific endogenous inhibitors of angiogenesis and tumor growth. Angiogenesis 2: 37-48, 1998

    Google Scholar 

  7. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Cao Y, Moses M, Lane WS, Sage EH, Folkman J: Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol. 59: 471-82, 1994

    Google Scholar 

  8. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression (see comments). Nat Med 1: 149-53, 1995

    Google Scholar 

  9. Kirsch M, Strasser J, Allende R, Bello L, Zhang J, Black PM: Angiostatin suppresses malignant glioma growth in vivo. Cancer Res 58: 4654-9, 1998

    Google Scholar 

  10. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394: 287-91, 1998

    Google Scholar 

  11. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-12, 1999

    Google Scholar 

  12. MacDonald NJ, Murad AC, Fogler WE, Lu Y, Sim BK: The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3. Biochem Biophys Res Commun 264: 469-77, 1999

    Google Scholar 

  13. Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B, O'Reilly M, Folkman J: Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD (in Process Citation). Proc Natl Acad Sci USA 95: 5579-83, 1998

    Google Scholar 

  14. Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, Borlat F, Sim BKL, Wu Z, Grau GE, Shing Y, Soff GA, Bouck N, Pepper MS: Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 92: 4730-41, 1998

    Google Scholar 

  15. Redlitz A, Daum G, Sage EH: Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells. J Vasc Res 36: 28-34, 1999

    Google Scholar 

  16. Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P, Soria C, Perricaudet M, Yeh P, Lu H: Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 95: 6367-72, 1998

    Google Scholar 

  17. Luo J, Lin J, Paranya G, Bischoff J: Angiostatin upregulates E-selectin in proliferating endothelial cells (in Process Citation). Biochem Biophys Res Commun 245: 906-11, 1998

    Google Scholar 

  18. Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA: Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 340: 77-84, 1999

    Google Scholar 

  19. Hoylaerts M, Rijken DC, Lijnen HR, Collen D: Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257: 2912-9, 1982

    Google Scholar 

  20. Silverstein RL, Nachman RL, Leung LL, Harpel PC: Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation. J Biol Chem 260: 10 346-52, 1985

    Google Scholar 

  21. Knudsen BS, Silverstein RL, Leung LL, Harpel PC, Nachman RL: Binding of plasminogen to extracellular matrix. J Biol Chem 261: 10 765-71, 1986

    Google Scholar 

  22. Stack S, Gonzalez-Gronow M, Pizzo SV: Regulation of plasminogen activation by components of the extracellular matrix. Biochemistry 29: 4966-70, 1990

    Google Scholar 

  23. Stack MS, Rinehart AR, Pizzo SV: Comparison of plasminogen binding and activation on extracellular matrices produced by vascular smooth muscle and endothelial cells. Eur J Biochem 226: 937-43, 1994

    Google Scholar 

  24. Moser TL, Enghild JJ, Pizzo SV, Stack MS: The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. J Biol Chem 268: 18 917-23, 1993

    Google Scholar 

  25. Ellis V, Whawell SA: Vascular smooth muscle cells potentiate plasmin generation by both urokinase and tissue plasminogen activator-dependent mechanisms: evidence for a specific tissue-type plasminogen activator receptor on these cells. Blood 90: 2312-22, 1997

    Google Scholar 

  26. Moser TL, Stack MS, Asplin I, Enghild JJ, Hj P, Everitt L, Hubchak S, Schnaper HW, Pizzo SV: Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 96: 2811-16, 1999

    Google Scholar 

  27. Gillies RJ: Angiostatin's partners (letter). Science. 284: 434, 1999

    Google Scholar 

  28. Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP, Soff GA, Kufe DW, Weichselbaum RR: Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 58: 5686-9, 1998

    Google Scholar 

  29. Drixler TA, Ritchie ED, Reyerkerk A, Aarsman CJM, Gebbink M, Brih M, Voest EE: Administration of angiostatin: Bolus or continuously? Proceedings of the American Association for Cancer Research Annual Meeting Vol. 40: 1999

  30. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-85, 1997

    Google Scholar 

  31. Muragaki Y, Timmons S, Griffith CM, Oh SP, Fadel B, Quertermous T, Olsen BR: Mouse Col18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones. Proc Natl Acad Sci USA 92: 8763-7, 1995

    Google Scholar 

  32. Sasaki T, Fukai N, Mann K, Gohring W, Olsen BR, Timpl R: Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J. 17: 4249-56, 1998

    Google Scholar 

  33. Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J: The generation of endostatin is mediated by elastase. Cancer Res 59: 6052-6, 1999

    Google Scholar 

  34. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W: Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 19: 1187-94, 2000

    Google Scholar 

  35. Gillies RJ, Liu Z, Bhujwalla Z: 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am J Physiol 267: C195-203, 1994

    Google Scholar 

  36. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance (see comments). Nature 390: 404-7, 1997

    Google Scholar 

  37. Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML, Simons M, Sukhatme VP: Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 59: 189-97, 1999

    Google Scholar 

  38. Sim BKL, Fogler WE, Zhou X, Liang H, Madsen JW, Luu K, O'Reilly MS, Tomaszewski J, Fortier AH: Zinc ligand-disrupted recombinant human Endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 3: 41-51, 1999

    Google Scholar 

  39. Ding YH, Javaherian K, Lo KM, Chopra R, Boehm T, Lanciotti J, Harris BA, Li Y, Shapiro R, Hohenester E, Timpl R, Folkman J, Wiley DC: Zinc-dependent dimers observed in crystals of human endostatin. Proc Natl Acad Sci USA 95: 10 443-8, 1998

    Google Scholar 

  40. Hohenester E, Sasaki T, Olsen BR, Timpl R: Crystal structure of the angiogenesis inhibitor endostatin at 1.5. A resolution. EMBO J 17: 1656-64, 1998

    Google Scholar 

  41. Hohenester E, Sasaki T, Mann K, Timpl R: Variable zinc coordination in endostatin. J Mol Biol 297: 1-6, 2000

    Google Scholar 

  42. Sasaki T, Larsson H, Kreuger J, Salmivirta M, Claesson-Welsh L, Lindahl U, Hohenester E, Timpl R: Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J 18: 6240-8, 1999

    Google Scholar 

  43. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowik C, Timpl R, Olsen BR: Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding EMBO J 18: 4414-23, 1999

    Google Scholar 

  44. Alberts IL, Nadassy K, Wodak SJ: Analysis of zinc binding sites in protein crystal structures. Protein Sci. (7): 1700-16, 1998

  45. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, Sukhatme VP: Endostatin induces endothelial cell apoptosis. J Biol Chem 274: 11 721-6, 1999

    Google Scholar 

  46. Salvesen GS, Dixit VM: Caspases: intracellular signaling by proteolysis. Cell 91: 443-6, 1997

    Google Scholar 

  47. Knebelmann B, Dhanabal M, Ramchandran R, Waterman M, Lu H, Sukhatme VP: Endostatin inhibits VEGF and bFGF induced MAPK activation in endothelial cells. Proceedings of the American Association for Cancer Research Annual Meeting. Vol. 40: 414, 1999

    Google Scholar 

  48. Chang Z, Choon A, Friedl A: Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding. Am J Pathol 155: 71-6, 1999

    Google Scholar 

  49. Dixelius J, Larsson H, Sasaki T, Holmqvist K, Lu L, Engstrom A, Timpl R, Welsh M, Claesson-Welsh L: Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 95: 3403-11, 2000

    Google Scholar 

  50. Berger AC, Feldman AL, Gnant MF, Kruger EA, Sim BKL, Hewitt S, Figg WD, Alexander HR, Libutti SK: The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J Surg Res 91: 26-31, 2000

    Google Scholar 

  51. Chen QR, Kumar D, Stass SA, Mixson AJ: Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice (see comments). Cancer Res 59: 3308-12, 1999

    Google Scholar 

  52. Liu Y, Thor A, Shtivelman E, Cao Y, Tu G, Heath TD, Debs RJ: Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J Biol Chem 274: 13 338-44, 1999

    Google Scholar 

  53. Sacco MG, Caniatti M, Cato EM, Frattini A, Chiesa G, Ceruti R, Adorni F, Zecca L, Scanziani E, Vezzoni P: Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer. Cancer Res 60: 2660-5, 2000

    Google Scholar 

  54. Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M, Singhal A, Sullivan S, Rolland A, Ralston R, Min W: Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene (in Process Citation). Nat Biotechnol 17: 343-8, 1999

    Google Scholar 

  55. Feldman AL, Restifo NP, Alexander HR, Bartlett DL, Hwu P, Seth P, Libutti SK: Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res 60: 1503-6, 2000

    Google Scholar 

  56. Griscelli F, Li H, Cheong C, Opolon P, Bennaceur-Griscelli A, Vassal G, Soria J, Soria C, Lu H, Perricaudet M, Yeh P: Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci USA 97: 6698-703, 2000

    Google Scholar 

  57. Nguyen JT, Wu P, Clouse ME, Hlatky L, Terwilliger EF: Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res 58: 5673-7, 1998

    Google Scholar 

  58. Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL: Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA 97: 4802-7, 2000

    Google Scholar 

  59. Tanaka T, Cao Y, Folkman J, Fine HA: Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 58: 3362-9, 1998

    Google Scholar 

  60. Dhanabal M, Volk R, Ramchandran R, Simons M, Sukhatme VP: Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun 258: 345-52, 1999

    Google Scholar 

  61. O'Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. (2): 689-92, 1996

  62. Lannutti BJ, Gately ST, Quevedo ME, Soff GA, Paller AS: Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 57: 5277-80, 1997

    Google Scholar 

  63. Drixler TA, Rinkes IH, Ritchie ED, van Vroonhoven TJ, Gebbink MF, Voest EE: Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res 60: 1761-5, 2000

    Google Scholar 

  64. Joe YA, Hong YK, Chung DS, Yang YJ, Kang JK, Lee YS, Chang SI, You WK, Lee H, Chung SI: Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. Int J Cancer 82: 694-9, 1999

    Google Scholar 

  65. Meneses PI, Abrey LE, Hajjar KA, Gultekin SH, Duvoisin RM, Berns KI, Rosenfeld MR: Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth. Clin Cancer Res 5: 3689-94, 1999

    Google Scholar 

  66. Yokoyama Y, Green JE, Sukhatme VP, Ramakrishnan S: Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Cancer Res 60: 4362-5, 2000

    Google Scholar 

  67. Perletti G, Concari P, Giardini R, Marras E, Piccinini F, Folkman J, Chen L: Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res 60: 1793-6, 2000

    Google Scholar 

  68. Soff GA: Angiostatin and angiostatin-related proteins. Canc Met Rev 19: 97-107, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. EntreMed Inc., Rockville, MD, USA

    B. Kim Lee Sim, Nicholas J. MacDonald & Edward R. Gubish

Authors
  1. B. Kim Lee Sim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas J. MacDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward R. Gubish
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim Lee Sim, B., MacDonald, N.J. & Gubish, E.R. Angiostatin and Endostatin: Endogenous Inhibitors of Tumor Growth. Cancer Metastasis Rev 19, 181–190 (2000). https://doi.org/10.1023/A:1026551202548

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026551202548

Search

Navigation